This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neu, H C
Right arrow Articles by Labthavikul, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neu, H C
Right arrow Articles by Labthavikul, P

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1986 December; 30(6): 828-834

In vitro activity against aerobic and anaerobic gram-positive and gram-negative bacteria and beta-lactamase stability of RS-533, a novel carbapenem.

H C Neu, N X Chin, G Saha and P Labthavikul

ABSTRACT

RS-533 is a novel carbapenem antibiotic. Its activity was compared with that of imipenem and the new cephalosporins, aztreonam, piperacillin, and tobramycin. RS-533 had activity comparable to that of imipenem, inhibiting the majority of the Enterobacteriaceae, streptococci, staphylococci, and Bacteroides species at concentrations of less than or equal to 2 micrograms/ml. RS-533 inhibited Enterobacter cloacae, Citrobacter freundii, and Serratia marcescens resistant to ceftazidime, aztreonam, and cefoperazone, but RS-533 did not inhibit all methicillin-resistant Staphylococcus aureus or Pseudomonas maltophilia. It inhibited tobramycin-resistant members of the Enterobacteriaceae and Pseudomonas aeruginosa. RS-533 was stable against attack by common chromosomal and plasmid-mediated beta-lactamases and was an effective inhibitor of many beta-lactamases.

Antimicrob Agents Chemother. 1986 December; 30(6): 828-834




This article has been cited by other articles:

  • Kobayashi, R., Konomi, M., Hasegawa, K., Morozumi, M., Sunakawa, K., Ubukata, K. (2005). In Vitro Activity of Tebipenem, a New Oral Carbapenem Antibiotic, against Penicillin-Nonsusceptible Streptococcus pneumoniae. Antimicrob. Agents Chemother. 49: 889-894 [Abstract] [Full Text]  
  • Ubukata, K., Chiba, N., Hasegawa, K., Kobayashi, R., Iwata, S., Sunakawa, K. (2004). Antibiotic Susceptibility in Relation to Penicillin-Binding Protein Genes and Serotype Distribution of Streptococcus pneumoniae Strains Responsible for Meningitis in Japan, 1999 to 2002. Antimicrob. Agents Chemother. 48: 1488-1494 [Abstract] [Full Text]  
  • Kato, N., Yamazoe, K., Han, C.-G., Ohtsubo, E. (2003). New Insertion Sequence Elements in the Upstream Region of cfiA in Imipenem-Resistant Bacteroides fragilis Strains. Antimicrob. Agents Chemother. 47: 979-985 [Abstract] [Full Text]  
  • Critchley, I. A., Karlowsky, J. A., Draghi, D. C., Jones, M. E., Thornsberry, C., Murfitt, K., Sahm, D. F. (2002). Activities of Faropenem, an Oral {beta}-Lactam, against Recent U.S. Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 46: 550-555 [Abstract] [Full Text]  
  • Hikida, M., Itahashi, K., Igarashi, A., Shiba, T., Kitamura, M. (1999). In Vitro Antibacterial Activity of LJC 11,036, an Active Metabolite of L-084, a New Oral Carbapenem Antibiotic with Potent Antipneumococcal Activity. Antimicrob. Agents Chemother. 43: 2010-2016 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»